December 29, 2016: Sell Eli Lilly for an 8.8% gain in 12 trading days. Congratulations if you were able to make money on the trade.
December 16, 2016: Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with Type 1 diabetes. This is a successful completion of an insulin pump study under the Adocia-Lilly partnership evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocias proprietary technology BioChaperone, designed to accelerate insulin absorption.
This study was the first to compare, in people with type 1 diabetes, the post-prandial glycaemia and pharmacokinetic response to an individualized mixed meal after a bolus of BioChaperone Lispro and Humalog(insulin lispro rDNA origin), administered with two different Continuous Subcutaneous Insulin Infusion (CSII) systems (Roche Accu-ChekSpirit and Medtronic ParadigmVeo) immediately before a meal. The study also investigated the effects of both agents administered subcutaneously with a syringe.
Exec: “We are pleased to confirm that BioChaperone Lispro consistently delivered ultra-rapid insulin absorption compared to Humalog in the two insulin pumps tested. This increased early insulin exposure translated into improved post-prandial glucose control. Thus, BioChaperone Lispro has demonstrated a consistent absorption profile across multiple studies, different populations, and, now, different delivery modes.”
This was a two-part study. The first part comparing the products in the Roche Accu-ChekSpirit pump did not clearly demonstrate an advantage for BioChaperone Lispro. The second part involved more subjects and included three devices: Roche Accu-ChekSpirit pump, Medtronic ParadigmVeopump and insulin syringe. In this latter part 44 subjects were enrolled in a randomized, double-blind, 2-treatment, 4-period cross-over, active controlled clinical trial to investigate BioChaperone Lispro compared to Humalog in CSII. During the treatment period, patients made four, 2-day visits to the clinic interspersed with wash-out periods. On the day of each visit, patients were subjected to a meal-tolerance test (MTT) after receiving one of the two treatments immediately prior to the meal using one of the two pumps (Day 1), or the same treatment using a syringe (Day 2) on top of basal delivery.
One primary objective of the second part of the study was to compare the absorption profile of BioChaperone Lispro vs. Humalog, when administered immediately before an individualized mixed meal, with the selected pump models and syringes. BioChaperone Lispro U100 demonstrated a statistically significant increase in insulin exposure over the first 30 minutes compared to Humalog in the two pumps tested: early exposure was increased by 33% in the Roche pump (primary endpoint, p=0.0007) and by 54% in the Medtronic pump (p<0.0001). This was consistent with a comparable increase of early insulin exposure for BioChaperone Lispro vs. Humalog using syringes on top of basal administration with a Roche pump (+71%, p<0.0001) and with a Medtronic pump (+83%, p<0.0001).
BioChaperone Lispro was associated with a consistent pattern of improved response to mixed meal testing compared to Humalog. In the Roche pump a statistically significant 83% reduction (p=0.0018) in the 2hr blood glucose excursion has been shown while a non-significant 12% reduction in the 2hr blood glucose excursion has been observed with the Medtronic pump. When delivered as a bolus from syringes, on top of basal delivery with an insulin pump, BioChaperone Lispro was also associated with significant reductions in the 2hr blood glucose excursion vs. Humalog (-56% with the Roche pump (p=0.0008) and -61% with the Medtronic pump (p<0.0001)).
Both BioChaperone Lispro and Humalog were similarly well tolerated. No new or unexpected safety findings were observed and no local reactions were seen on the site of administration for either treatment.
The registry on clinicaltrials.gov for this trial (NCT02562313) has been updated.
December 15, 2016: Morgan Stanley raised Eli Lilly to an Overweight rating, from Equal Weight, and set a price of target of $82.
December 15, 2016: Goldman Sachs adds Eli Lilly to its conviction buy list.
December 15, 2016: Eli Lilly and Co BASAGLAR (insulin glargine injection 100 units/mL), a long-acting Basal Insulin, is now available in the U.S. Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced today that BASAGLAR(insulin glargine injection 100 units/mL) is available by prescription in the U.S. BASAGLAR is a follow-on insulin to Lantus. It is a long-acting insulin with an amino acid sequence identical to Lantus, another U-100 insulin glargine.
In December 2015, the U.S. Food and Drug Administration (FDA) approved BASAGLAR as a long-acting insulin used to control high blood sugar in adults and children with type 1 diabetes and adults with type 2 diabetes. BASAGLAR should not be used to treat diabetic ketoacidosis. BASAGLAR should not be used during episodes of low blood sugar (hypoglycemia) or in people with an allergy to insulin glargine or any of the ingredients in BASAGLAR.
With resources designed to be simple, BASAGLAR goes beyond just insulin by offering helpful support for people beginning insulin. These bilingual resources include an app for smartphones and tablets to provide an interactive experience that helps patients relax and guides them through injection using their BASAGLAR KwikPen, injection demo kits (available through HCPs), and access to educational videos. Do NOT reuse needles or share insulin pens, even if the needle has been changed.
BASAGLAR will be available by prescription from retail and mail order pharmacies across the U.S. As the top three pharmacy benefit managers have selected BASAGLAR for their formularies, it is expected to be widely covered by commercial insurance plans. In addition, Lilly and Boehringer Ingelheim will offer a BASAGLAR savings card for eligible people.
December 12, 2016: Eli Lilly and Company said to offer a 40% discount on top insulin products for patients with no health coverage or have high deductibles, bypassing insurance companies. I didn’t know drug makers could do that. Let’s see if insurance companies try and take Eli Lilly to court.
December 12, 2016: Eli Lilly and Company raised their dividend 2% to $0.52 from $0.51 (indicated yield 3.1%). The dividend is payable March 10, 2017, to shareholders of record at of the close of business on February 15, 2017.
December 12, 2016: The U.S. Food and Drug Administration (FDA) has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be taken. It is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY).
SYNJARDY XR is a combination of empagliflozin and metformin two medicines with complementary mechanisms of action to help improve blood glucose in adults with type 2 diabetes. Empagliflozin, a sodium-glucose co-transporter 2 inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. SYNJARDY XR is the fourth FDA-approved treatment that contains empagliflozin. Metformin, a commonly prescribed initial treatment for type 2 diabetes, lowers glucose production by the liver and its absorption in the intestine.
The FDA approval of SYNJARDY XR is based on results from multiple clinical trials examining the co-administration of empagliflozin and metformin, alone or in combination with sulfonylurea, in the treatment of adults with type 2 diabetes. SYNJARDY XR is not for the treatment of type 1 diabetes or diabetic ketoacidosis.
December 5, 2016: Piper Jaffray reiterates an Overweight rating on Eli Lilly, and sets a price target of $97.
Eli Lilly Stock Chart
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.